FDA grants breakthrough designation to rapid test for xylazine, veterinary sedative fueling overdose crisis

A Pennsylvania diagnostics company has received a key federal designation for a rapid urine test designed to detect xylazine, a veterinary sedative that has become a dangerous and growing presence in the nation's illicit drug supply.

Instanosis Inc. announced this week that the U.S. Food and Drug Administration has granted Breakthrough Device Designation to its Xylazine Rapid Test (Urine), a move the company says will accelerate the device's path to market.

Xylazine — sometimes called "tranq" — is not approved for human use but has been increasingly found mixed with fentanyl and other synthetic opioids in street drug supplies across the United States. The combination has alarmed public health officials because naloxone, the medication widely used to reverse opioid overdoses, has no effect on xylazine. The drug has been linked to severe respiratory depression, prolonged sedation and complex soft tissue wounds that can lead to amputation.

The FDA's Breakthrough Device Designation program is intended to speed the development and regulatory review of medical devices that may offer more effective diagnosis or treatment of life-threatening or irreversibly debilitating conditions. Companies that receive the designation gain prioritized communication and review from the agency.

"The FDA's Breakthrough Device Designation is a significant milestone for our development program," said Xiaofeng Xia, chief operating officer of Instanosis. "This designation enables enhanced interaction with the Agency as we execute our clinical and regulatory strategy to deliver a reliable, rapid xylazine detection solution to the market."

The Instanosis test is designed for use by health care providers, laboratories and public health professionals to identify potential xylazine exposure and improve awareness of shifting substance use patterns in their communities.

Instanosis was founded in Pennsylvania and focuses on developing rapid testing technologies for clinical and community settings.

Advances in rapid diagnostics for emerging drug threats

The Instanosis designation arrives amid a broader push across the diagnostics industry to develop faster, more versatile tools capable of keeping pace with a rapidly evolving illicit drug landscape.

For much of the past decade, point-of-care drug testing focused primarily on traditional substances such as opioids, benzodiazepines, amphetamines and cocaine. But the rise of synthetic opioids, novel psychoactive substances and adulterants like xylazine has forced developers to rethink both the scope and speed of their testing platforms.

Lateral flow immunoassay technology — the same basic mechanism behind at-home COVID-19 and pregnancy tests — has emerged as a leading approach for rapid drug detection because it requires minimal equipment, can be performed outside of a laboratory setting and typically delivers results in under 15 minutes. Researchers have worked to extend this format to detect a widening range of substances, including synthetic cannabinoids, nitazenes and fentanyl analogs that traditional assays frequently miss.

Mass spectrometry, long considered the gold standard for confirmatory drug testing, has also been refined and miniaturized in recent years. Portable and benchtop versions of the technology are increasingly being evaluated for deployment in emergency departments, harm reduction programs and medical examiner offices, where rapid, highly specific identification of unknown substances can directly inform clinical decisions.

Multiplexing — the ability to test for multiple substances simultaneously from a single sample — represents another significant area of progress. Newer platforms can screen for dozens of compounds at once, reducing turnaround times and costs compared to running separate tests for each target analyte.

Public health agencies have also worked to integrate rapid testing data into real-time surveillance systems, allowing local and national authorities to track the emergence of new substances more quickly than traditional forensic reporting pipelines allow. That kind of near-real-time intelligence has become increasingly valuable as the composition of the drug supply has grown more unpredictable, with new adulterants and synthetic compounds appearing faster than regulatory and clinical frameworks can easily accommodate.

The combination of faster assay development timelines, more sensitive detection chemistries and broader regulatory support through programs like the FDA's Breakthrough Device Designation has given the field new momentum as it tries to close the gap between what is circulating on the street and what clinicians can reliably identify at the bedside.